Did You Know?
More women will die annually of the ramifications of a broken hip, than from breast cancer.
Every woman goes through menopause. Some women are lucky and have fewer symptoms than others, although research shows that 70-80% of women do suffer significant symptoms.
A lot of women who come for treatment are worried about HRT and it’s potential to cause cancer. However, this is not correct – there is an extremely low correlation between the two. Our genetic screening can help give women peace of mind with an indication of their individualized risk factors.
The average length of symptoms during menopause is 7 years. This number can vary from woman to woman and can even last anywhere from 10 to 15 years. This means that even women in their 60s or 70s can benefit from genetic screenings and HRT.
Consider this quick and painless genetic test that specifically screens for the proven genetic predispositions for breast cancer, ovarian cancer, and the most common genetic blood clotting disorders.
A Controversial topic affecting all women—the role of hormone replacement therapy through menopause and beyond
(Apple Podcasts)
Why Taking Hormones in Menopause Can Improve Women's Well-Being and Lengthen Their Lives - Without Raising the Risk of Breast Cancer
The North American Menopause Society (NAMS)
Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM) and has been shown to prevent bone loss and fracture.
BMD During the Pre or Early Perimenopause
Bone loss accelerates substantially in late perimenopause and continues at a similar pace in the first postmenopausal years.
Body Weight and Ethnicity In Relation to BMD
A similar study of bone mineral density changes during menopause reveals that bone loss accelerates substantially in the late perimenopause and continues at a similar pace in the first postmenopausal years. Additionally, the rate of postmenopausal bone mineral changes is related to body weight and not ethnicity.